Company overview
biomodal offers the duet multiomics solution, +modC, which simultaneously captures genetic and epigenetic data (A, C, G, T, 5mC, 5hmC) from a single low-volume DNA sample (as low as 5ng) in one sequencing run. This technology enables comprehensive analysis for applications in cancer research, precision medicine, and disease biology studies. Formerly Cambridge Epigenetix, biomodal provides tools that enhance accuracy, efficiency, and depth of biological insights for life sciences and pharma R&D.
Explore biology in every mode is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include multiomics sequencing, epigenetic analysis, genetic sequencing, cancer research tools, precision medicine.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://biomodal.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- multiomics sequencing, epigenetic analysis, genetic sequencing, cancer research tools, precision medicine
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is biomodal's core technology?
- biomodal's duet multiomics solution, +modC, is a single-base-resolution sequencing technology that reads genetic (A, C, G, T) and epigenetic (5mC, 5hmC) information simultaneously from a single 5ng DNA sample in one workflow.
- What are the key applications for biomodal's solutions?
- Key applications include cancer research (DNA methylation alterations), precision medicine (tailored treatments using genetics and epigenetics), and studies in ageing, normal biology, and disease.
- What sample input is required for biomodal's sequencing?
- The technology requires just 5ng of DNA for multiomic analysis, enabling high sensitivity from low-volume samples.
Related editorial coverage
- Bio-IT World Conference: Oncology Highlights - Day 1
- BioMed Israel 2024: Key Innovations and US Partnerships
- US-Japan Healthcare Conf: Key Takeaways for 2026
- Oncology Data Landscape 2026: Key Trends & Upcoming Readouts
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- Brazilian Oncology Market: Growth of Precision Medicine & Biomarker Testing
Explore lab tools and QA/QC resources for R&D teams.
